Antiverse

Antiverse is a Cardiff-based AI-driven antibody discovery company founded in 2017. The company has built a platform that designs therapeutic-grade antibodies against some of medicine's most difficult drug targets — G-protein coupled receptors (GPCRs) and ion channels — which are implicated in over 200 diseases but have fewer than ten FDA-approved antibody treatments. These targets have resisted conventional discovery approaches because they are highly dynamic proteins embedded in cell membranes that rarely survive purification in a functional state.

Antiverse's platform uses machine learning models trained on seven years of proprietary data to generate antibody candidate sequences computationally, designed from first principles to bind to specific epitopes on target proteins. These candidates are then built in the company's own laboratories and tested on proprietary cell models that display target proteins as they appear in the human body — in their native membrane context, at physiologically relevant expression levels. This lab-in-the-loop cycle of design, build, test, and iterate allows Antiverse to produce therapeutic-grade antibodies against difficult targets in approximately four months, compared to the one-to-three-year timelines associated with conventional approaches.

Antiverse has secured collaboration agreements with multiple top-20 global pharmaceutical companies including Nxera, and entered a research agreement with the Cystic Fibrosis Foundation to design antibodies targeting the extracellular region of CFTR. The company is headquartered in Cardiff's sbarc|spark Social Science Research Park, with additional offices in Boston and Prague.

Antiverse raised $9.3 million (£7 million) in a Series A in March 2026, led by Soulmates Ventures, with participation from Innovation Investment Capital, DOMiNO Ventures, and existing investors including the Development Bank of Wales, Kadmos Capital, and i&i Biotech Fund. Total funding now exceeds $20 million since founding.